Ultragenyx Pharma Projects FY24 Revenue To Surpass Its Expectations

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) said it expects total revenue for 2024 to be in the range of $555 million to $560 million, which exceeds the updated guidance range provided in August 2024, and represents approximately 29% growth versus 2023.

Crysvita revenue for 2024 is estimated to be $405 million to $410 million, which also exceeds the guidance range, and represents approximately 24% growth versus 2023. Dojolvi revenue for 2024 is estimated to be $87 million to $89 million, also exceeding the guidance range, and represents approximately 25% growth versus 2023.

For 2025, the company projects total revenue to be between $640 million and $670 million and the company expects to provide guidance on 2025 Crysvita and Dojolvi revenue as part of its fourth quarter and fiscal year 2024 financial disclosures in February 2025.